Windlas Biotech Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nkgsrydoi47qph78i9gph6h5.pdf

Key Takeaways


CDMO: The Core Growth Driver

Hitesh Windlass: "This is something that we've built in -- having this electronically is a big advantage, and we are one of the few organizations who have done it in the Indian market."

Exports: High Reward, Binary Risk


Trade Generics & Institutional: Absorbing the Codeine Shock


Capacity & Capital Allocation

Hitesh Windlass: "We do not want -- or we do not see ourselves doing a capex, which is like 5 years kind of we're creating capacity for the next 5 years. We want to do it more like 1.5 to 2.5 years kind of chunk. And that's the sweet spot that we believe is most suitable for us."

New Dosage Forms & Inorganic Strategy

Hitesh Windlass: "One of the things that has been very important discipline for us has been that we don't want to walk into somebody else's problem. Even if it is coming for a very cheap price because a lot of effort goes into fixing something that is really -- you don't know the depth of it when you are buying a new -- into a new business."

Margins & Cost Environment


Guidance & Commitments

CommitmentSpecificsTimeline
Plant 6 commercializationMechanical completion done; commercialization on trackH1 FY27
Revenue capacity post-Plant 6~₹1,000 cr (ex-injectables at ₹100 cr), with 10-15% efficiency upsideAs plant commercializes
Organic capexNo organic capex expected beyond maintenance capexFY27
Next capacity additionAdditional capacity possible if very good numbers deliveredFY28
Working capital rangeNo significant variation expected from current 20-25 daysOngoing
EU GMP approvalReadiness and preparedness on track; timeline not disclosedNo timeline given

Key Metrics

MetricQ4 FY26
Revenue₹238 cr, +18% YoY
FY26 revenue₹904 cr, +19% YoY
CDMO revenue₹176 cr, +20% YoY; 73% of total revenue
Trade generics & institutional revenue₹46 cr, flat YoY; FY26 grew 13% to ₹195 cr
Export revenue₹17 cr, +67% YoY; FY26 grew 40% to ₹46 cr
Reported EBITDA₹25 cr, FY26 grew 11% to ₹105 cr
Adjusted EBITDA₹33 cr, 13.6% margin; FY26 ₹121 cr, 13.4% margin
Reported PAT₹16 cr, FY26 rose 9% to ₹66 cr
Adjusted PAT₹23 cr, 9.7% margin; FY26 ₹83 cr, 9.2% margin
EPS (FY26, post-listing highest)₹31.60
ROCE and ROEAbove 25% (FY26)
Net operating cash flow (FY26)₹105 cr
Net liquidity position₹251 cr (FY26 closing)
Customer concentrationTop customer 6.5%, top 10 at 32%, top 20 at 40-41% of revenue (FY26)
Working capital days20–25 days, reduced from ~40 days; sustained for ~3 years
Plant 6 peak revenue potential~₹1,000 cr (excluding injectables ~₹100 cr); company-level capacity ready for ~₹1,100 cr
Capacity expansion headroom10–15% further efficiency unlock possible beyond stated peak levels
Dividend proposed (FY26)₹6.3 per share, total ₹13 cr
Buyback completed₹47 cr, without promoter participation